Table 2.
Histopathological features and follow-up outcomes.
| No-PPAP (n = 32) | PPAP (n = 32) | p | |
|---|---|---|---|
| Tumor dimension (cm), median (QR) | 2.19 (1.85–2.98) | 2.21 (1.77–3.01) | 0.63 |
| TNM staging, n (%) | |||
| I | 18 (56.2) | 11 (34.4) | 0.21 |
| II | 11 (34.4) | 16 (50) | |
| III | 3 (9.4) | 5 (15.6) | |
| Harvested lymph nodes, median (QR) | 18.5 (14–26) | 22.5 (16–27) | 0.1 |
| Positive lymph nodes, median (QR) | 2 (1–2.5) | 2 (1–2.5) | 0.91 |
| Tumor grading, n (%) | |||
| G1 | 5 (15.6) | 6 (18.8) | 0.67 |
| G2 | 24 (75) | 21 (65.6) | |
| G3 | 3 (9.4) | 5 (15.6) | |
| Follow up (months), median (QR) | 33 (12.6–118.1) | 24.4 (17.9–76.5) | 0.79 |
| Adjuvant chemotherapy, n (%) | 12 (37.5) | 17 (53.1) | 0.81 |
| Recurrence, n (%) | 11 (34.4) | 16 (50) | 0.2 |
| Site of recurrence, n (%) | |||
| Local | 2 (6.3) | 3 (9.4) | 0.97 |
| Distant | 9 (28.1) | 13 (40.6) |